BioKeralty develops predictive software for diabetes and cognitive impairment
The tool proposes a new salutogenic approach for the prevention, diagnosis and treatment of metabolic syndrome and coexisting pathologies
In the context of the Supreme project, BioKeralty has worked in the creation of an in vitro system with iPS and other related lines to test molecules, active ingredients and new drugs destined to the treatment of cognitive impairment.
July 30, 2021
Under the scope of Supreme project, BioKeralty and Keralty group’s laboratory unit have worked together on the design of a software that includes a predictive model able to estimate the risk of complications derived from Diabetes Mellitus Type 2 (T2D). In addition, in a more advanced version, the software also allowsresearch of cognitive impairment.
The global approach of Supreme project and Keralty’s interest in each product and service included in this project make more attractive the integration of the salutogenic approach in the design of new health care and health management models. More specifically, the three distinctive aspects of project have consisted in a predictive software for Type 2 Diabetes Mellitus (T2D), a personalized medicine comprehensive service and an advanced in vitro model for the study of cognitive impairment.
The Supreme project has developed a diabetes predictive software, a personalized medicine comprehensive service and an advanced in vitro model for cognitive impairment
The new software represents a certified technological product that includes a machine learning trained algorithm that will allow the prediction of T2D related problems which remarks its high preventive role. In terms of personalized medicine comprehensive service, Supreme has established the fundamentals for the future development of a system able to analyze quantitatively the risk of suffering from T2D. As predictive tool, it will allow the integration of new tools to develop other personalized medicine applications (food supplements, effective diets, etc.) avoiding those costs derived from incorrect medical prescriptions. Finally, regarding the advanced in vitro model for the study of cognitive impairment, BioKeralty has worked in the creation of an in vitro system with iPS and other related lines (such as, an advanced in vitro platform) to test molecules, active ingredients and new drugs destined to the treatment of cognitive impairment.
Launched in 2019, the Supreme project (which is formed by a consortium of nine leading Basque companies of the food, pharmaceutical, IT and healthcare sector) has come to its end. Under the premise of the development of a new salutogenic approach for the prevention, diagnosis and treatment of those pathologies related with aging, this strategic project has been financed by the Hazitek Program of the Basque Government. Despite the pandemic, the project has met the majority of its objectives. In the case of Keralty, since 2017 the group has integrated the salutogenesis in the co-creation of care models, understanding this concept as a useful tool to stand out in the health services provision industry and contribute, at the same time, to the creation of employment and the training of this sector’s professionals.
For those people interested in the scientific publications and patents developed by the BioKeralty team, this section gathers detailed information and useful references corresponding to its scientific research. Nanomaterials, biomedical applications, in vitro and in vivo antimicrobial activities, nanomedicine, fatty acids, nanofibrous membranes, tissue reparations, etc. constitute some of the research topics included in this section.